S&P 500   3,006.46 (+0.68%)
DOW   26,817.22 (+0.18%)
QQQ   193.37 (+0.88%)
AAPL   240.84 (+1.87%)
FB   189.10 (+1.75%)
MSFT   138.14 (+0.52%)
GOOGL   1,244.65 (+0.02%)
AMZN   1,781.32 (+1.35%)
CGC   20.44 (+1.14%)
MU   45.22 (+4.03%)
BABA   172.90 (+2.23%)
GE   8.84 (-1.34%)
AMD   32.19 (+3.94%)
T   38.26 (-0.55%)
F   9.05 (-2.58%)
ACB   3.70 (+0.54%)
PRI   125.65 (+1.72%)
NFLX   275.97 (+0.24%)
BAC   31.02 (+2.17%)
GILD   65.26 (+0.54%)
DIS   130.51 (-0.29%)
S&P 500   3,006.46 (+0.68%)
DOW   26,817.22 (+0.18%)
QQQ   193.37 (+0.88%)
AAPL   240.84 (+1.87%)
FB   189.10 (+1.75%)
MSFT   138.14 (+0.52%)
GOOGL   1,244.65 (+0.02%)
AMZN   1,781.32 (+1.35%)
CGC   20.44 (+1.14%)
MU   45.22 (+4.03%)
BABA   172.90 (+2.23%)
GE   8.84 (-1.34%)
AMD   32.19 (+3.94%)
T   38.26 (-0.55%)
F   9.05 (-2.58%)
ACB   3.70 (+0.54%)
PRI   125.65 (+1.72%)
NFLX   275.97 (+0.24%)
BAC   31.02 (+2.17%)
GILD   65.26 (+0.54%)
DIS   130.51 (-0.29%)
Log in

Beigene Stock Price, News & Analysis (NASDAQ:BGNE)

$133.50
+1.22 (+0.92 %)
(As of 10/21/2019 02:21 PM ET)
Today's Range
$131.66
Now: $133.50
$133.85
50-Day Range
$115.97
MA: $128.46
$144.78
52-Week Range
$105.19
Now: $133.50
$164.99
Volume227,774 shs
Average Volume290,138 shs
Market Capitalization$6.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.99
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
CUSIPN/A
Phone1-345-949-4123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$198.22 million
Book Value$29.52 per share

Profitability

Net Income$-673,770,000.00
Net Margins-153.32%

Miscellaneous

Employees2,070
Market Cap$6.34 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.


Beigene (NASDAQ:BGNE) Frequently Asked Questions

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.01) by $1.58. The company had revenue of $243.35 million for the quarter, compared to the consensus estimate of $65.58 million. Beigene had a negative return on equity of 38.41% and a negative net margin of 153.32%. The firm's revenue was up 360.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.92) EPS. View Beigene's Earnings History.

When is Beigene's next earnings date?

Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Beigene.

What price target have analysts set for BGNE?

8 brokers have issued 1 year price targets for Beigene's stock. Their forecasts range from $170.00 to $201.00. On average, they expect Beigene's stock price to reach $185.00 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price. View Analyst Price Targets for Beigene.

What is the consensus analysts' recommendation for Beigene?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 sell rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.

Has Beigene been receiving favorable news coverage?

Press coverage about BGNE stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Beigene earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Beigene.

Who are some of Beigene's key competitors?

What other stocks do shareholders of Beigene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Adobe (ADBE) and Celgene (CELG).

Who are Beigene's key executives?

Beigene's management team includes the folowing people:
  • Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
  • Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
  • Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Who are Beigene's major shareholders?

Beigene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Brinker Capital Inc. (0.01%) and Sumitomo Mitsui DS Asset Management Company Ltd (0.00%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

Which major investors are buying Beigene stock?

BGNE stock was acquired by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank , Brinker Capital Inc. and Sumitomo Mitsui DS Asset Management Company Ltd. View Insider Buying and Selling for Beigene.

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $133.50.

How big of a company is Beigene?

Beigene has a market capitalization of $6.34 billion and generates $198.22 million in revenue each year. The company earns $-673,770,000.00 in net income (profit) each year or ($12.15) on an earnings per share basis. Beigene employs 2,070 workers across the globe.View Additional Information About Beigene.

What is Beigene's official website?

The official website for Beigene is http://www.beigene.com/.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]


MarketBeat Community Rating for Beigene (NASDAQ BGNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  740
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel